Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05689645 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

F573 for Injection for the Treatment of Liver Injury/Failure

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 19, 2025 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 25, 2025 to Sep 1, 2026
    • Study completion date: Mar 31, 2026 to Sep 1, 2026
    v7
  2. Study sites: 7 to 10
    • Eligibility criteria expanded, about 92 words
    v6
  3. Study sites: 6 to 7v5
  4. Eligibility criteria shortened, about 43 words
    • Secondary endpoints revised (91)
    • Study description expanded, about 77 words
    v4
  5. Enrollment target: 90 to 97v3
  6. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Enrollment target: 120 to 90
    • Study sites: 0 to 6
    • Start date changed from estimate of Jan 18, 2023 to Mar 24, 2023
    • Eligibility criteria shortened, about 355 words
    • Secondary endpoints revised (91)
    • Study description expanded, about 10 words
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial . The primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury (DILI), chronic hepatitis B (CHB), intrahepatic cholestatic liver injury, etc.).
Trial Details
NCT Number NCT05689645
Lead Sponsor Beijing Continent Pharmaceutical Co, Ltd.
Conditions
(from sponsor)		 Acute Liver Failure, Acute-On-Chronic Liver Failure
Related terms Acute-On-Chronic Liver Failure, Liver Failure, Acute
Enrollment 97 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov